Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Accumulated Depreciation: 2023-2025

Historic Accumulated Depreciation for Artiva Biotherapeutics (ARTV) over the last 1 years, with Sep 2025 value amounting to $7.8 million.

  • Artiva Biotherapeutics' Accumulated Depreciation rose 46.63% to $7.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.8 million, marking a year-over-year increase of 46.63%. This contributed to the annual value of $5.9 million for FY2024, which is 67.70% up from last year.
  • According to the latest figures from Q3 2025, Artiva Biotherapeutics' Accumulated Depreciation is $7.8 million, which was up 9.02% from $7.2 million recorded in Q2 2025.
  • In the past 5 years, Artiva Biotherapeutics' Accumulated Depreciation registered a high of $7.8 million during Q3 2025, and its lowest value of $3.5 million during Q4 2023.
  • For the 3-year period, Artiva Biotherapeutics' Accumulated Depreciation averaged around $6.0 million, with its median value being $6.2 million (2024).
  • Data for Artiva Biotherapeutics' Accumulated Depreciation shows a peak YoY soared of 67.70% (in 2024) over the last 5 years.
  • Over the past 3 years, Artiva Biotherapeutics' Accumulated Depreciation (Quarterly) stood at $3.5 million in 2023, then soared by 67.70% to $5.9 million in 2024, then spiked by 46.63% to $7.8 million in 2025.
  • Its Accumulated Depreciation was $7.8 million in Q3 2025, compared to $7.2 million in Q2 2025 and $6.5 million in Q1 2025.